of the upper gastrointestinal tract are more common in iron deficient patients with webs than those without, suggesting that autoimmunity is a factor in Paterson-Kelly syndrome. It is reported that treatment with iron and correction of anaemia may sometimes relieve dysphagia but without necessarily altering the radiological appearance of the web itself. Whether such treatment has any effect on the estimated 5% risk of malignant change in the pharyngo-oesophageal region is uncertain. 4 Oesophageal web remains an uncommon cause of dysphagia in childhood but one which may be suggested by careful history taking and clinical examination. Barium swallow can be diagnostic but false negative or misleading results sometimes occur particularly if reluctance to drink the barium results in poor dilatation of the pharynx insufficient for the web to be visualised. 2 The lack of information regarding postcricoid dysphagia in childhood makes the prognosis for our patient impossible to define. When the diagnosis is not made until adult life there may be a history of dysphagia going back to childhood. One such case, a male diagnosed at the age of 38, developed squamous cell carcinoma of the pharynx 10 years later.6 Our patient has so far only Dysphagia due to oesophageal web 143 been followed up for a few months but as the risk of malignancy is particularly worrying in a young child we plan to keep him under regular review with repeat pharyngoscopy at six monthly intervals, whether symptomatic or not. SUMMARY The study consisted of two 14 day periods, one while taking the usual dose of Pancrease and the other while taking Cotazym-S-Forte. The number of Cotazym-S-Forte capsules was calculated to be half the usual number of Pancrease capsules. When the number of Pancrease capsules was an odd number the lower half was taken. Patients were randomly allocated to commence with either Pancrease or Cotazym-S-Forte. Sixteen patients took Pancrease in the first 14 day period of the study and 14 Cotazym-S-Forte. Each 14 day period terminated with a three day fat balance study performed at home. This consisted of a full dietary recording for four days with a faecal collection during the last three days of this period. No restriction was placed on fat intake during the study period. As a further check that the fat intake was similar in both periods and represented by the dietary record at the end of the period, however, a further two days of dietary recording was performed mid way through each 14 day period separate from the recording period for the fat balance study.
Faecal fat estimation was calculated using the acid titration method of van High compared with standard dose lipase pancreatic supplement 145 the medication. Despite instructions to reduce the number of capsules by only half when taking Cotazym-S-Forte, some patients reduced it by more than half without any significant alteration in fat malabsorption. This does not negate the results of this study as the aim of this study was to determine if Cotazym-S-Forte was as effective as Pancrease, not that it necessarily had better activity.
Individual Thus the microsphere size may be the reason why some patients were able to reduce their capsule intake to less than half their usual Pancrease dose without an alteration in the degree of fat malabsorption. Another possible and more likely explanation for the reduction in enzyme intake by more than half is that these patients were taking an excessive number of Pancrease capsules initially.
All patients involved with the study expressed preference for the Cotazym-S-Forte preparation due to the reduced number of capsules required. No side effects were noted. The diarrhoea experienced by one patient while on Cotazym-S-Forte is unlikely to have been a side effect as several members of his family, who do not have cystic fibrosis, had similar symptoms at the same time. The preparation appears to be safe and acceptable.
With the advent of enteric coated pancreatic supplements our ability to provide adequate nutrition in cystic fibrosis has improved due to the greater utilisation of fat as an energy source. While it remains likely that in the foreseeable future enzymes will still be needed, a reduction in the number of capsules required would be of major benefit to these patients.
The results of this study have shown that Cotazym-S-Forte is as effective as Pancrease in correcting fat malabsorption in cystic fibrosis and has the added advantage of needing only about half the number of capsules. Congenital epulis of the newborn is a rare, benign tumour of the gingiva first described in 1871.1 The aetiology and histological origin of the tumour are unknown and there are still doubts as to the natural history of the condition. The optimal management of congenital epulis is unclear and some authors have recommended simple excision in the neonatal period.2 This report concerns an infant who pre-
